Observational Study
Copyright ©The Author(s) 2019.
World J Gastroenterol. Jul 7, 2019; 25(25): 3256-3267
Published online Jul 7, 2019. doi: 10.3748/wjg.v25.i25.3256
Table 1 The baseline characteristics of the enrolled treatment-naïve chronic hepatitis B patients with normal or minimally raised alanine aminotransferase levels
Characteristics (n = 63)
Sex, male/female37/26
Age, mean (± SD) yr50.8 (± 8.9)
Body mass index, mean (± SD) kg/m223.4 (± 3.4)
AST, mean (± SD), IU/L (normal 4-40 IU/L)43.5 (± 22.6)
ALT, mean (± SD), IU/L (normal 4-40 IU/L)44.0 (± 20.8)
Platelet counts, mean (± SD), × 103/mm3163.5 (± 39.4)
Prothrombin time, mean (± SD), INR1.05 (± 0.08)
Total bilirubin, mean (± SD), mg/dL0.75 (± 0.47)
Albumin, mean (± SD), g/dL3.97 (± 0.24)
γ-glutamyl transferase, mean (± SD), U/L47.5 (± 31.0)
HBeAg status, positive/negative35/28
HBV-DNA, mean (± SD), log10 IU/mL5.78 (± 1.64)
Grade of inflammatory activity (0/1/ 2/3)9/26/15/13
Fibrosis stage (0/1/2/3 /4)3/16/14/ 14/16
Table 2 Statistics of liver stiffness value measured by magnetic resonance elastography and two-dimensional shear wave elastography, fibrosis index based on four factors score, and aspartate transaminase-to-platelet ratio index score with the Spearman’s coefficients according to fibrosis stages
F0/F1 (n = 19)F2 (n = 14)F3 (n = 14)F4 (n = 16)rP value
MRE1.96 ± 0.432.46 ± 0.542.91 ± 0.453.91 ± 0.500.869< 0.001
2D-SWE6.09 ± 1.588.05 ± 2.238.16 ± 2.0811.39 ± 3.010.649< 0.001
FIB-41.75 ± 0.611.76 ± 0.602.48 ± 0.913.21 ± 1.450.517< 0.001
APRI0.58 ± 0.200.71 ± 0.460.95 ± 0.441.04 ± 0.580.431< 0.001
Table 3 Factors associated with the values of liver stiffness measured by magnetic resonance elastography and two-dimensional shear wave elastography in univariate and multivariate linear regression analyses
ParametersFactors associated with liver stiffness values by MRE
Factors associated with liver stiffness values by 2D-SWE
UnivariateP valueMultivariateP valueUnivariateP valueMultivariateP value
Sex, male/female-0.054 (-0.508, 0.401)0.8150.685 (-0.840, 2.210)0.372
Age, yr0.019 (-0.006, 0.044)0.1320.067 (-0.017, 0.151)0.117
BMI, kg/m2-0.048 (-0.114, 0.018)0.149-0.251 (-0.469, -0.034)0.024-0.186 (-0.366, -0.007)0.042
AST, U/L0.007 (-0.003, 0.017)0.1570.032 (-0.001, 0.065)0.054
ALT, U/L0.002 (-0.009, 0.013)0.6740.000 (-0.037, 0.037)0.995
PLT counts, × 103/mm3-0.007 (-0.012, -0.001)0.0140.001 (-0.002, 0.005)0.530-0.027 (-0.045, -0.009)0.004-0.012 (-0.029, 0.004)0.136
PT, INR1.312 (-1.595, 4.220)0.3708.658 (-0.971, 18.288)0.077
Total bilirubin, mg/dL0.331 (-0.140, 0.802)0.1650.098 (-1.517, 1.713)0.904
Albumin, g/dL-0.540 (-1.510, 0.429)0.270-3.152 (-6.359, 0.055)0.054
γ-GT, U/L0.004 (-0.003, 0.011)0.3020.012 (-0.012, 0.036)0.327
HBeAg status, +/-0.166 (-0.282, 0.615)0.4611.052 (-0.445, 2.549)0.165
HBV-DNA, log10 IU/mL-0.051 (-0.189, 0.086)0.456-0.076 (-0.541, 0.389)0.745
Inflammatory grade0.363 (0.153, 0.573)0.0010.105 (-0.031, 0.241)0.1290.903 (0.163, 1.644)0.0180.220 (-0.411, 0.852)0.487
Fibrosis stage0.626 (0.520, 0.732)< 0.0010.609 (0.487, 0.731)< 0.0011.616 (1.116, 2.116)< 0.0011.276 (0.690, 1.863)< 0.001
Table 4 Diagnostic performance of magnetic resonance elastography and two-dimensional shear wave elastography, fibrosis index based on four factors score, and aspartate transaminase-to-platelet ratio index for evaluation of significant fibrosis (≥ F2) and cirrhosis (F4)
AUC (95%CI)P valueCutoffSensitivity (%)Specificity (%)PPV (%)NPV (%)
MRE≥ F20.906 (0.806, 0.965)< 0.001> 2.47 (kPa)81.894.797.369.2
F40.894 (0.791, 0.958)< 0.001> 3.46 (kPa)88.997.894.195.6
2D-SWE≥ F20.843 (0.730, 0.923)< 0.001> 6.73 (kPa)84.168.486.065.0
F40.816 (0.698, 0.902)< 0.001> 9.50 (kPa)77.880.060.990.0
FIB-4≥ F20.697 (0.568, 0.806)0.003> 1.8070.563.281.648.0
F40.786 (0.665, 0.880)< 0.001> 3.2250.097.890.083.0
APRI≥ F20.717 (0.590, 0.823)0.001> 0.4984.152.680.458.8
F40.701 (0.572, 0.810)0.006> 0.9650.084.456280.9